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Cancer and atherosclerosis are major causes of death in western societies. Deregulated cell death is common to both diseases,
with signiﬁcant contribution of inﬂammatory processes and oxidative stress. These two form a vicious cycle and regulate cell
death pathways in either direction. This raises interest in antioxidative systems. The human enzymes paraoxonase-2 (PON2)
and PON3 are intracellular enzymes with established antioxidative eﬀects and protective functions against atherosclerosis.
Underlying molecular mechanisms, however, remained elusive until recently. Novel ﬁndings revealed that both enzymes locate
to mitochondrial membranes where they interact with coenzyme Q10 and diminish oxidative stress. As a result, ROS-triggered
mitochondrialapoptosisandcelldeatharereduced. Fromacardiovascular standpoint,thisisbeneﬁcial giventhatenhanced lossof
vascular cells and macrophage death forms the basis for atherosclerotic plaque development. However, the same function has now
been shown to raise chemotherapeutic resistance in several cancer cells. Intriguingly, PON2 as well as PON3 are frequently found
upregulated in tumor samples. Here we review studies reporting PON2/PON3 deregulations in cancer, summarize most recent
ﬁndings on their anti-oxidative and antiapoptotic mechanisms, and discuss how this could be used in putative future therapies to
target atherosclerosis and cancer.
1.Introduction
Most studies in the ﬁeld of paraoxonases (PONs) deal with
cardiovascular diseases, such as atherosclerosis and diabetes,
where PONs exert protective functions in cell culture as
well as animal studies. It has been anticipated that the
known antioxidative functions of PONs, including PON2
and PON3, were central to their eﬀects although underlying
molecular mechanisms remained obscure. However, recent
ﬁndings caused a signiﬁcant progress in this ﬁeld because
molecularpathwaysofPON2andPON3functionshavebeen
largely revealed. Moreover, the result of the cell-protective
function were shown to play a vital role in survival and stress
resistance of cancer cells, along with the ﬁnding that numer-
ous tumors overexpressed these enzymes. There, PON2 and
PON3 appear to increase chemotherapeutic resistance and
favor cell survival. In this review, we summarize the most
recent ﬁndings and discuss the role of PON2/PON3 in
atherosclerosis and cancer. A future perspective gives an
outlook on how PONs may be targets of novel therapeutic
approaches.
2. Altered Expression Levels of Paraoxonase
Enzymes inCancer
Itis established thatoxidative stressfrom mitochondria plays
an important role in apoptosis and also leads to premature
aging and cancer. There is growing scientiﬁc consensus that
antioxidants or proteins with antioxidative functions, such
as paraoxonases, can lower the incidence of, for example,
cardiovascular and neurodegenerative diseases. On the other
hand, recent studies have shown that various types of cancer
obviously take advantage of this protection by enhanced
expression of the antioxidative paraoxonase proteins. In
the following section, we give an overview of studies that2 Journal of Lipids
assessed expression of PON1, PON2, or PON3 in various
cancers, with the majority of studies seemingly reporting a
deregulation of these proteins.
PON1levelsandactivityarelowerinmanyinﬂammatory
and oxidative stress-associated diseases [1]. Also, serum
PON1 and arylesterase activities were reduced in patients
with epithelial ovarian cancer [2] and lung cancer [3]. Uyar
et al. found that Q allele of PON1 was more frequent in renal
cancerpatients[4],andAntognelliatal.reportedthatcertain
PON1 genotypes were prone to increased risk of prostate
cancer [5]. More recently, the presence of the variant alleles
of the Q192R and L55M SNPs of PON1, both of which result
in an amino acid replacement that alters PON1 activity, were
found associated with a 18–29% increased risk of aggressive
prostate cancer [6]. These studies clearly demonstrate a link
between PON1 and cancer etiology; however, PON1 is not
the scope of this review. We will focus on the role of PON2
and PON3 in cancer based on recent discoveries on the
mechanism of action of these proteins in proliferation and
apoptosis.
Research on paraoxonases is a relatively young ﬁeld,
and still much of our understanding comes from ﬁndings
related to PON1. Back in 1999, our knowledge about PON2
and PON3 was extremely limited although few studies
emerged that reported genetic associations with metabolic
diseases [7]. There are two common single nucleotide
polymorphisms (SNPs) in PON2—G148A and C311S—that
have been associated with disease phenotypes. In essence,
an association between these SNPs and several diseases
was demonstrated. For PON2-G/A148 this is true, for
instance, for higher plasma glucose [8], higher plasma HDL
cholesterol [9], and lower plasma LDL cholesterol [10].
With respect to S/C311, Stoltz et al. reported that this
mutation determines the lactonase activity of PON2 which
links to hydrolysis of important bacterial virulence factors
[11]. However, a subsequent study from our lab did not
conﬁrm this ﬁnding [12]. The impact of PON2-S/C311 on
lactonehydrolysisthusmeritsfurtherinvestigation.Thismay
similarly apply for its role in coronary heart disease, where
at least one study reported an association [13] that was not
found in a subsequent meta-analysis [14].
Despite the established and prevailing role of paraox-
onases in cardiovascular diseases and relevant parameters,
more recent studies revealed an emerging association of
PONswithcancer.Forexample,microarraystudiesobserved
an overexpression of PON2 in some solid tumors like
hepatocellular carcinoma, prostate carcinoma [15, 16], and
several others, which are illustrated in Table 1. Additionally,
in various leukemia gene expression proﬁling studies, an
upregulation of PON2 could be demonstrated; an example is
pediatric acute lymphoblastic leukemia (ALL) [17]. Impor-
tantly, a subsequent study identiﬁed PON2 as member of
a very small group of upregulated genes that characterized
pediatric ALL patients with very poor outcome prognosis
[18]. In another form of leukemia, chronic myeloid leukemia
(CML), PON2 was also identiﬁed in an outcome-speciﬁc
gene expression signature of primary imatinib-resistant
patients [19]. Moreover, a marked overexpression of PON2
was observed in lymphocytes infected with T-cell leukemia
virus [20].
In contrast to PON2, there are fewer studies for PON3
with the tendency of more diverse results (see Table 2). For
instance, a downregulation was demonstrated in a meta-
analysis of expression proﬁles in hepatocellular carcinomas
(HCC) [21] and in ovarian serous papillary carcinomas
(OSPCs) [22] shown by oligonucleotide microarrays. How-
ever, there are various other such analyses, which showed
altered expression of PON3 (up as well as downregulated)
in diﬀerent types of cancers. For overview, consult the
Gene Expression Atlas found at http://www.ebi.ac.uk/gxa/.
In general, it should be noted that these association studies
show no direct proof for a physiological relevance of these
proteins in cancer, nor do such studies give any clues about
their functions and mechanisms.
In addition to the listed microarray data, our very
recent analyses showed that the PON2 level is increased in
some tumors at the protein level (Table 1). We showed a
moderate PON2 overexpression in pancreas, liver, kidney,
and lung tumors and an over 10-fold upregulation of
PON2 in thymus tumors and non-Hodgkins lymphomas
[23]. Assessment of PON2 protein levels is not feasible
in hundreds of cancer samples. Therefore, we previously
used cDNA arrays, developed for diﬀerential gene expression
analysis and validation of hundreds of diﬀerent human
tissues. We showed that PON2 is ∼2–4-fold overexpressed
in the tumors from urinary bladder, liver, kidney, lymphoid
tissues, and endometrium/uterus in comparison to normal
tissue [23], which are in accordance with western blot
analyses. Despite some other tissues, where no increase in
the expression level was observed, human tumors of the
thyroid gland, testis, prostate, and pancreas showed a slight
upregulation of PON2 (Table 1).
Using the same cDNA arrays as for PON2, our group
showed a considerably increased PON3 expression in all
tested cancer types, except cervix [24]. Remarkably, the
intensity of PON3 overexpression was markedly enhanced
compared to that of PON2. In this array over 10-fold
upregulation of PON3 in tumors from endometrium/uterus
and stomach was shown and over 3-fold induction in
samples from pancreas, urinary bladder, thyroid, prostate,
pancreas, liver testis, and lung cancers. These results could
be veriﬁed with another matched array particularly for
lung cancer (normal versus diseased samples from the same
patient). But in contrast to PON2, PON3 expression appears
to be largely restricted to cells derived from solid tumors
[24]. One reason for the high expression level of PON3 in
cancer tissue is certainly the low basal expression level of
PON3 in healthy tissues but may nevertheless suggest a role
for PON3 in cell death escape.
An interesting phenomenon is obvious upon closer
inspection of the array data. A tumor subtype and stage-
speciﬁc analysis revealed that both PON2 and PON3 are
upregulated rather in the early stages and some subtypes of
cancer, whereas the expression in the late stages of the tumor
seems to be declining (see Figure 1). This could indicate
that, especially in the early stages of tumor formation,
the antioxidative and antiapoptotic function of PON2 andJournal of Lipids 3
Table 1: Expression levels of PON2 in various tumor tissues and/or cancer cell cultures. Microarray experiment (array express) listings are
according to the Gene Atlas Database. Protein and cDNA levels according to [23]. Cell culture expression levels were roughly estimated as
relative level comparing to A549, grouped into low, medium, or high.
Tissue (cancer) Protein level (fold
of normal tissue)
cDNA array (fold
of normal tissue) Microarray studies Cell culture (expression level in
cell line)
Kidney 2 2.2 Upregulated in renal carcinoma
(E-MTAB-37) Medium (HEK293)
Liver 1.7 2.2 Overexpressed (Li et al. [15]) High (Huh7/HepG2)
Lung 1.3 1
Upregulated in lung adenocarcinoma
(E-MEXP-231/E-MTAB-37)
Downregulated in small cell lung
carcinoma (E-GEOD-4127)
High (A549; H661; H1299)
Spleen 0.5 n/a
Pancreas 1.4 1.6 Upregulated in pancreatic carcinoma
(E-MTAB-37)
Thymus 11.5 n/a
Urinary bladder n/a 4.1 High (HT1367/RT112)
Esophagus n/a 0.6 Upregulated in esophageal cancer
(E-MTAB-62)
Stomach n/a 1 Upregulated in gastric carcinoma
(E-GEOD-2685)
Ovar n/a 1 Upregulated (E-MTAB-62)
Cervix n/a 1 Upregulated
(E-MTAB-37/E-MTAB-62) Medium (HeLa)
Adrenal gland n/a 1 Downregulated in adrenocortical
carcinoma (E-TABM-311)
Thyroid gland n/a 1.4 Upregulated
(E-GEOD-3467/E-GEOD-3678)
Prostate n/a 1.6 Overexpressed (Ribarska, T. et al. [16]
E-MTAB-62)
Testis n/a 1.7 Low (SuSa/GCT27/833K)
Uterus/endometrium n/a 2.1
Lymphoid tissue n/a 2.5
Leukemias (various) n/a Upregulated in pediatric ALL
(Ross et al. and Kang et al. [17, 18])
Low in AML-like Nalm6/EOL;
Jurkat Tcells; PML-like
HL60/HCW2; CML-like KCL
Medium in blast crisis line K562;
CML-like lama; AML-like
THP1/MonoMac6/HEL
Non-Hodgkin 11.9 n/a Downregulated (E-MTAB-37)
PON3 is important and beneﬁcial as it helps generating
the platform for malignant transformation. This could
represent a potential approach of innovative therapies trying
to normalize the otherwise overexpressed PONs.
A ﬁrst direct hint to this theory came from our recent
study demonstrating that PON2 increased chemoresistance
in leukemic cells [23], which is in line with genetic associa-
tion studies where PON2 upregulation was associated with
imatinib resistance in CML patients [19] and poor prognosis
in cohorts of pediatric ALL [17, 18]. In support of the
hypothesis, the same study [23] revealed that knockdown
of endogenous PON2 caused spontaneous apoptosis of
severalhumancancercelllines—anintriguingbutsomewhat
unexpected ﬁnding given the viability of PON2-deﬁcient
mice (the residual PON2 expression in these mice [25]m a y
be comparable to eﬃcient cell culture RNAi experiments).
An exciting question is how tumors achieve an increase
in PON2 and/or PON3 expression, and this should be a
major goal of future studies. Certainly there is no general
answer to this question. Most likely, underlying mechanisms
are individual for each given tumor. One simple explanation
could be that, in some tissues, for example, papillary
renal cell kidney carcinoma or prostate adenocarcinoma,
chromosome 7, which contains the PON cluster, is ampliﬁed
[16]. Another reason might be that the regulation depends
on several signaling pathways, which are linked to reactive
oxygen species and cancer, for example, PPAR-γ,A P - 1 ,
β-catenin/Wnt, NF-κB, HIF-1α,P I 3 K ,a n dN r f 2[ 26]. In
accordance, earlier studies showed that PON2 expression
is enhanced by oxidative stress [27], PI3K/PDGFR, PPARγ,
and NADPH oxidase activation as well as by AP-1 activation
[28, 29]. The urokinase plasminogen activator (uPA) system4 Journal of Lipids
Table 2: Expression levels of PON3 in various tumor tissues and/or cancer cell cultures. Microarray experiment (array express) listings are
according to the Gene Atlas Database. cDNA levels according to [24]. Cell culture expression levels were roughly estimated as relative level
comparing to A549, grouped into low, medium, or high.
Tissue (cancer) cDNA array (fold
of normal tissue) Microarray studies
Cell culture
(expression level in
cell line)
Kidney 2.2 Downregulated in clear cell sarcoma of the kidney
(E-GEOD-2712/E-TABM-282)
Not detectable
(HEK293)
Liver 4.9 Downregulated in hepatocellular carcinoma (HCC)
(Choi et al. [21])
High (Huh7)
Medium (HepG2)
Lung 3.4 Upregulated in lung adenocarcinoma
(E-MTAB-37/E-MTAB-62)
Medium (A549)
Pancreas 3.2 Upregulated in pancreatic carcinoma (E-MTAB-37)
Urinary bladder 3.8
Not detectable
(HT1367/RT112)
Esophagus 1.8
Stomach 9.5
Ovar 2.1 Downregulated in ovarian serous papillary carcinomas
(OSPCs) (Santin et al. [22])
Cervix 0.5 Downregulated in cervical carcinoma (E-MTAB-62)
U p r e g u l a t e di nc e r v i c a lc a r c i n o m a( E - M T A B - 3 7 )
Not detectable
(HeLa)
Adrenal gland 1.5
Thyroid gland 2.6 Downregulated in papillary thyroid carcinoma
(E-GEOD-3467)
Prostate 4.5 Downregulated in prostate carcinoma (E-MTAB-62)
Testis 5.3
Not detectable
(SuSa/GCT27/833K)
Uterus/endometrium 16.2
Lymphoid tissue 2.3
Leukemias (various) n/a
Not detectable in
AML-like Nalm6;
Jurkat Tcells;
PML-like
HL60/HCW2 blast
crisis line K562;
CML-like lama;
AML-like THP1
high in CML-like
KCL
Non-Hodgkin n/a Downregulated (E-MTAB-37)
may also be relevant, as this is increased in numerous cancers
and upregulates PON2 [29].
A point of interest is why some tumors upregulate PON2
or PON3. One of the hallmarks of cancer is resistance to
cell death [30]. It has been found that paraoxonases 2 and
3 provide a protection against mitochondrial cell death sig-
naling [23, 24]. Their overexpression lowered susceptibility
to diﬀerent chemotherapeutics (e.g., imatinib, doxorubicin,
and staurosporine) in cell culture models via diminishing
proapoptotic mitochondrial O2
− formation. It is established
that oxidative stress and chronic inﬂammation are closely
linked to cell death and cancer [26]. Therefore, it appears
conceivable that tumors take advantage of the antioxidative
function of PON2/PON3 to escape cell death.
3.The Antioxidative
Mechanisms of PON2/PON3
Inﬂammation and oxidative stress contribute to the etiology
of almost every known disease. Reactive oxygen species gen-
eratedbyenzymaticandnonenzymaticsystemsmodifylipids
and sterols, producing oxidized lipids and oxidized sterols
that, if unchecked, produce a vicious cycle of undesirable
inﬂammation and more oxidative stress. Atherosclerosis is
a chronic inﬂammatory disease characterized by the focal
accumulation of numerous cells, lipids, and extracellular
matrices in the intima of arteries. Although reduced levels
of high density lipoprotein (HDL) and elevated levels of
low density lipoprotein (LDL) cholesterol are acceptedJournal of Lipids 5
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Figure 1: PON2 and PON3 are found overexpressed in early rather than late stages of tumors. Indicated cancer tissues were analyzed for
PON2/PON3 cDNA levels (normalized to GAPDH) relative to healthy controls. Values were taken from recently performed arrays [23, 24].
risk factors for this disease, atherogenesis cannot solely be
explained by cholesterol or lipid deposition in the arterial
wall. Accumulating evidence suggests that oxidative stress
plays a fundamental role in atherosclerosis. In particular,
the oxidation theory for atherosclerosis proposes that LDL
is a major target of oxidation and is involved in both the
initiation as well as progression of atherosclerosis [31].
Although there has been a focus on PON1 due to its
association with HDL, a number of studies demonstrated
thatPON2andPON3protectcellsandtissuesfromoxidative
stress by reducing reactive oxygen species [1, 25, 32–37].
PON2andPON3caninhibitLDLoxidationandenhancethe
antioxidantpropertiesandcholesteroleﬄuxcapacityofHDL
even though they are not readily found on the lipoproteins
[1, 25, 32–37]. Moreover, in animal models, both PON2
and PON3 have been shown to abrogate the development of
atherosclerosis [25, 35, 38]. These preclinical studies clearly
demonstrated that PON2 and PON3 (similar to PON1) are
(a) anti-atherogenic and (b) targets for therapy. However, to
date, the physiological substrates and roles for PON2 and
PON3 have not been elucidated, which similarly applies to
PON1.
Recent studies suggest that PON2 [12, 38, 39] and PON3
[24] modulate the levels of reactive species in cells and in
animal models demonstrating for the ﬁrst time a physio-
logical molecular link between PON proteins and oxidative
stress. Based on the earlier result that PON2 was found in
subcellular mitochondrial fractions [40], Altenh¨ ofer et al.
demonstrated that PON2 prevents the ubisemiquinone-
mediated mitochondrial superoxide generation and apop-
tosis independent of its lactonase activity [12]. During Q
cycle, unstable intermediate ubisemiquinone (coenzyme Q10
[CoQ10
−]) can donate electron to molecular oxygen (instead
of cytochrome c) leading to superoxide production and
reduced ETC activity [41–43]. Devarajan et al. reported that
(a) PON2 is present in the inner mitochondrial membrane
(IMM), and (b) binds with high aﬃnity to coenzyme Q10
(CoQ10), an important component of the ETC [38]. Steady-
state concentrations of ubisemiquinone are increased in the
IMM resulting in superoxide formation when treated with
inhibitors of ETC, antimycin, or rotenone [43]. Devarajan
et al. demonstrated that overexpression of PON2 reduces
superoxide levels induced by either antimycin or rotenone
suggesting that PON2 sequesters ubisemiquinone. More-
over, PON2-deﬁcient mice harbour reduced ETC complex
I + III activities, oxygen consumption, ATP levels, and
enhanced mitochondrial oxidative stress further suggesting
that PON2 maintains the respiratory chain by promoting
the sequestration of the unstable reactive intermediate
ubisemiquinone, thereby preventing the superoxide produc-
tion. Supporting our hypothesis, previously, it has been
shown that mitochondrial superoxide is inversely related to
the amount of CoQ10 bound to membrane proteins [44].
Similar to PON2, Schweikert et al. have demonstrated that
PON3 is also localized to mitochondria, protects against
mitochondrial oxidative stress, and demonstrated that Q10
is associated with puriﬁed PON3-GFP protein [24]. This
illustrates that the antiatherogenic eﬀects of PON2/3 are,
in part, mediated by their role in mitochondrial function
(Figure 2). Since increased production of reactive oxygen
species (ROS) as a result of mitochondrial dysfunction play
a role in the development of many inﬂammatory diseases
including atherosclerosis, the recent data on PON2 and
PON3 provide a mechanistic direction for the scores of
epidemiological studies that show a link between PON
proteins and numerous inﬂammatory diseases including
Type II diabetics and cancer.6 Journal of Lipids
Atherosclerosis and insulin resistance are multifacto-
rial diseases that are commonly associated with dyslipi-
demia, oxidative stress, obesity, hypertension, and chronic
inﬂammation. The liver is not only the primary site of
lipid metabolism, but is a major site for glucose uptake,
production, and storage. Its role in glucose metabolism is
strongly inﬂuenced by systemic as well as local oxidative
and inﬂammatory stimuli [45, 46], which in turn inﬂuences
whole-body insulin responsiveness [47]. Hepatic glucose
metabolism is strongly inﬂuenced by oxidative stress and
proinﬂammatory stimuli. Given the elevated oxidative stress
levels and abnormal lipid metabolism reported previously in
PON2-deﬁcient mice [25, 38], Bourquard et al. hypothesized
thatatherosclerosismaybeaccompaniedbyimpairedhepatic
insulin signaling and showed that PON2 deﬁciency is asso-
ciated with inhibitory insulin-mediated phosphorylation of
hepatic insulin receptor substrate-1 (IRS-1) [39]. Factors
secreted from activated macrophage cultures derived from
PON2-deﬁcient mice are suﬃcient to modulate insulin
signaling in cultured hepatocytes in a manner similar to
that observed in vivo [39]. It was further demonstrated
that modulation of hepatic insulin sensitivity by PON2 is
mediated by a shift in the balance of NO and ONOO
−
(peroxynitrite) formation. These studies show that PON2
plays an important role in insulin sensitivity by its ability to
modulate reactive species most likely as a result of PON2’s
association with mitochondrial function.
Oxidative stress has long been associated with the
pathophysiology of cancer. In particular, enhanced ROS
formation increases DNA damage, genome instability, and
cell proliferation especially during cancer initiation. On the
other hand, oxidative stress also counteracts tumorigenesis,
as it induces senescence and drives apoptosis and other cell
death pathways [48]. The precise spatiotemporal control of
ROSgenerationisthereforeacriticalregulatorofcellsurvival
and death, for instance since overwhelming mitochondrial
oxidative stress exerts apoptotic rather than protumorigenic
functions. Nevertheless, reactive oxygen species may be
conducive to the vitality of cancer cells and drive signaling
transduction pathways, which lead to activation of redox-
sensitive transcription factors and genes involved in cancer
cell growth, proliferation, and survival [26]. In conclusion,
PON2 and PON3 reduce oxidative stress and inﬂammation
andthusactascentralregulatorsofdiseases,includingcancer
and atherosclerosis.
4. Paraoxonases and the Regulation of
Cell Death
The antioxidative eﬀects of PON2 and PON3 were reported
long ago, but underlying mechanisms were uncovered just
recently [12, 24, 38]. This similarly applies to the cell
death-reducing activity of PON2, where discovery [40]a n d
mechanistic realization [23] were separated by years. Based
on the latest knowledge, these enzymes modulate execution
of the apoptotic program. In this chapter, we review their
involvementinapoptosisanddiscusstheirputativefunctions
in other cell death pathways.
Tumor cells evolve a plethora of strategies to resist cell
death with the intrinsic apoptotic program being implicated
as a major barrier to cancer formation. Execution of
intrinsic cell death is mainly controlled by the balance
of pro- and antiapoptotic Bcl-2 protein family members
[30, 49], because they regulate mitochondrial pore opening
and cytochrome C release. Importantly, it also requires
intramitochondrial redox signaling to liberate cytochrome
C from its membrane attaching molecule, cardiolipin [50,
51]. In fact, this is a two-step process because neither
mitochondrialmembranepermeabilizationalonenorredox-
triggered disruption of the cytochrome C/cardiolipin inter-
action suﬃciently activates the cascade. Recent studies
revealed that PON2 and PON3, due to interaction with
coenzyme Q10, diminish O2
− release on either side of the
inner mitochondrial membrane [23, 24]. This results in
both lowered cardiolipin peroxidation and cytochrome C
release, providing a marked resistance against apoptosis.
Thus, if a cancer cell needs to escape from mitochondrial
redox-dependent cell death, it appears beneﬁcial to increase
PON2 or PON3 expression. In accordance, both enzymes
protected against a range of chemotherapeutics when over-
expressed [23, 24]. In contrast, receptor-mediated apoptosis
was unchanged, at least in type-I cells, where stimulation
with TRAIL or TNF-α directly activated caspases 8 and
3. This may be diﬀerent for type-II cells, which involve
mitochondrial actions.
Another important stress and cell death pathway is the
unfolded protein response (UPR) as a result of insurmount-
able ER stress [52]. Both PON2 and PON3 protected against
UPR-mediated apoptosis in a similar manner, that is, by
negativemodulationofJNKsignaling,CHOPinduction,and
subsequent caspase activation [12, 23, 24]. Canonical UPR
signaling (via ATF6, XBP1, or p-eIF2a) was unchanged, at
least by PON2, so their precise mechanisms of protection
remain uncertain. Future studies must reveal if PON2/PON3
act just through their mitochondrial eﬀects or if they
modulate signaling from IRE1 to TRAF2/ASK1, from the
ER to mitochondria or local ROS/Ca2+ responses and
how they reduce JNK phosphorylation. Interestingly, PON2
overexpression was induced by ER stress and protected
against UPR-triggered cell death, but this was lost upon
major disturbances of Ca2+—homeostasis, presumably by
calpain-dependent PON2 degradation [53]. Our current
studies suggest that this similarly applies to PON3 ([54]
this issue and data not shown). The postulated functions of
PON2 and PON3 in apoptosis and ER stress-induced cell
death are summarized in Figure 3.
A vital physiologic response that regulates cellular
metabolismandsurvivalisautophagy.Thispathwayoperates
at low basal levels but can be markedly increased under
speciﬁc stress conditions. It enables breakdown of macro-
molecular structures and organelles to allow recycling of
catabolites. Therefore, autophagy may alleviate nutrient
limitation as experienced by many cancer cells. However,
autophagy has opposing eﬀects on diﬀerent tumor cells and
may cause survival of one but death of the other [55].
Whether paraoxonases modulate this pathway is unknown
and no interaction with Bcl-2 family/autophagy-relatedJournal of Lipids 7
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Figure 2: Schematic presentation of the suggested antioxidative mechanism of PON2 and PON3. A current model for the role of PON2/3
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proteins has been reported. On the other hand, oxidative
stress is mutually linked with autophagy, and there it plays
an important role in cancer therapy resistance and tumor
progression. The connection between ROS and autophagy
is illustrated, for instance, by TNFα-induced signaling in
sarcoma cells [56], or by the autophagy-relevant factor Atg4
whose delipidating activity is sensitive to mitochondrial
H2O2 production [57]( s e e[ 58]f o rad e t a i l e do v e r v i e w
of this topic). Paraoxonases hence could have a profound
impact on autophagy due to their central redox eﬀects.
B e c a u s ea u t o p h a g yb yR O Sc a ns e r v ea sr e s c u ep a t h w a yb u t
may also initiate autophagic cell death, it requires more in-
depth evaluation including the origin and targets of ROS.
In a similar manner, this may also be true for necroptosis
(or necrotic cell death), which contrasts with the chemical-
or injury-triggered necrosis and represents another, RIP1
kinase-dependent programmed cell death pathway. Necrop-
tosis is of relevance, for example, for damages resulting
from ischemia-reperfusion, such as stroke or myocardial
infarction. Moreover, necrotic cell death may paradoxically
be even beneﬁcial to neoplasias as this form of cell death
attracts tumor-promoting inﬂammatory cells [30]. TNF-
induced necroptosis has been shown to generate complex-
I-mediated ROS in mitochondria, which is crucial to this
process and accounts for ultrastructural changes observed in
such cells [59]. Because PON2 as well as PON3 were able
to reduce superoxide released from mitochondrial complex-I
[12, 24, 38], it would hence be a promising endeavor to test
PONs in TNF-induced necroptosis.
Another hallmark of tumor cells is the reprogramming
of glucose metabolism in order to provide eﬃcient fueling
of the high energy demand associated with rapid cancer
growth. For the most part, this is manifested as a switch
to (aerobic) glycolysis but also involves two diﬀerent cancer
cell subpopulations—one using glucose and a second set
consuming lactate produced by the former (see [30]a n dr e f -
erences therein). How overexpressed PONs could play a role
in this system has not been explored, and speculations can8 Journal of Lipids
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Figure 3: Schematic presentation of the suggested antiapoptotic mechanism of PON2 and PON3. Its ability to prevent mitochondrial O2
−
formation impacts on both ER stress-induced pathways (via acting on JNK and CHOP) as well as mitochondrial proapoptotic signaling
such as cardiolipin peroxidation and cytochrome C release. See text for details. From our current understanding, PON2 is functionally
interchangeable with PON3.
only be extrapolated from the PON2-deﬁcient mice. Intrigu-
ingly, mitochondria from PON2 deﬁcient mice produced
less ATP, had impaired complex-I and -III activities, and
showed enhanced oxidative stress and consumed less oxygen,
resulting in an overall exhausted mitochondrial function
[38]. Thus, if the opposite was true for PON2 overexpressing
cells, this would ensure mitochondrial functionality and
could support the energy eﬃcacy of tumor cells.
Despite a role of paraoxonases directly in cancer cells, it
could also be interesting to scan for other near-by functions.
Cancer progression is determined by intracellular changes in
the malignant cell itself, but also modulated by surrounding
stromalcellsinthetumormicroenvironment. Itiscomposed
ofleukocyteinﬁltratesconsisting,forexample,ofendothelial
cells, mast cells, T cells, and tumor-associated macrophages
(TAMs). The protumorigenic TAMs are involved in crit-
ical features of neoplastic cells (such as migration &
metastasis), in the inﬂammatory tumor microenvironment,
angiogenesis, survival under hypoxia, and immune evasion
[60]. Although most research groups that work on PONs
employ macrophages, no study addressed TAMs to our
knowledge. PON2 expression is enhanced during mono-
cyte to macrophage diﬀerentiation in a ROS-dependent
manner [28], but it is uncertain how the established anti-
inﬂammatory and antioxidative eﬀect of PON2 could ﬁt
particularly into TAM functions. Thus, it may be worthwhile
t oa s s e s sP O N 2l e v e l si nM 1v e r s u sM 2m a c r o p h a g e s .O n e
may speculate that TAMs have low levels of PON2, which
would favor ROS formation and inﬂammatory responses
[25, 38] and may also increase production of the metastasis-
augmenting IL-1β (at least, the latter has been shown for
PON2 knockdown in endothelial cells [61]). Alternatively,
given that TAMs represent an interesting therapeutic target
[60], monitoring their recruitment in tumors of wild-type
mice compared to those deﬁcient in PON2 or PON3 mice
may also uncover new aspects of both paraoxonases and
TAM inﬁltration with potential therapeutic implications. A
direct role of PON3 in TAMs may be unlikely considering
that PON3 appeared undetectable in human macrophages
[27].
5.FuturePerspectives
5.1.ManipulationofPONExpression:ADouble-EdgedSword?
The relevance of PON2 and PON3 to the cancer ﬁeld has
beendemonstratedonlyrecently.Fewstudiesaddressedtheir
direct role, and our current knowledge appears somewhat
fragmented. However, much of their antiapoptotic mech-
anism has been revealed. This allows tentative evaluation
of their pharmacological usefulness. We presented multipleJournal of Lipids 9
lines of evidence demonstrating that PON2 and PON3 are
frequently found upregulated in cancer samples. Speciﬁc
regulatory mechanisms are mostly unknown. The altered
expression appears similar but also distinct for each of the
two enzymes, varying with the tissue itself, with the speciﬁc
kind of tumor and its stage, progression, diﬀerentiation,
and/or metastasizing potency (see above). Up to now, two
studies directly analyzed PON2 and PON3 levels in a variety
of diﬀerent tumors or representative cell lines [23, 24].
Addressing this question from the opposite direction, many
independent laboratories used microarrays to investigate
gene expressions in diﬀerent tumors and often (though not
always) found enhanced levels of these enzymes (see above).
Our current understanding allows to conclude that
overexpression of PON2/PON3 diminishes the execution
of the apoptotic program. Most likely, the antioxidative
function of these enzymes represents the antiapoptotic
trigger,whereasthecontributionoftheirenzymaticactivities
remains unknown, if at all signiﬁcant. How this works in the
ER and relates to the UPR that is unknown. In the simplest
model, however, this refers to electron transport within the
inner mitochondrial membrane, which is in close proximity
to and control of powerful apoptotic modiﬁers. From such
perspective, upregulation of PON2 or PON3 in cells destined
for apoptotic evasion appears consequential. As a logical
deduction, the controlled reduction of overexpressed PON2
and/or PON3 in a given tumor may represent a novel
approach to enhance its susceptibility to chemotherapeutics
and to improve the therapy’s eﬀectiveness. Such hypothesis
is encouraged by the observation that PON2 knockdown
induced spontaneous apoptosis of several human tumor
cell lines and because overexpression of either PON2 or
PON3 granted robust chemotherapeutic resistance [23, 24].
PON2/PON3 expression varied substantially between diﬀer-
ent cell types, and high levels did not automatically correlate
with cellular responsiveness to its knockdown. This outlines
that individual approaches must be identiﬁed because PON2
and PON3, similar to already established targets, are unlikely
to be beneﬁcial in every setting. Therefore, future studies
need to identify a rapid, reliable, and simple read-out
system to monitor if a given tumor relies on high PON
levels. This should be worthwhile, for example, in leukemic
transformation in pediatric B-precursor ALL, where PON2
was among a very small group of factors highly expressed in
patients with worst outcome, high risk, and aﬀected relapse-
free survival [18]. Other rewarding projects may be deduced
from Table 1, where we summarized the combination (if
available) of studies reporting PON2 overexpression in a
giventumor.ThereislimitedevidenceforPON3sinceweare
justbeginningtounderstanditsfunctionandbecausePON3,
compared to PON2, is expressed to much lower levels and
in fewer tissues. Given our recent data [24], we nevertheless
conclude PON3 also represents a molecule actively involved
in cell death regulation.
Can we then simply strive for a systemic downregulation
of PON2/PON3 in selected cancer therapies and if so,
which speciﬁc risks could be expected? PON2-deﬁcient
mice were in a pronounced inﬂammatory status [25]a n d
suﬀered from a series of other defects linked to severe
malfunctions (Witte & Horke; unpublished). Furthermore,
(i) reduced PON2 levels enhanced atherogenesis in mice
[25,38],modulatedmonocytechemotaxisandcell-mediated
LDL oxidation [25, 32], and correlated with atheroscle-
rosis progression in humans [62]; (ii) PON2 may have a
neuroprotective role [63]; (iii) genetic associations linked
PON2 with amyotrophic lateral sclerosis [64], Alzheimer
disease [65], microvascular complications in diabetes [66],
coronary heart disease [67], or perhaps also obesity [68];
(iv) PON2 plays a dominant role in the hydrolysis of bac-
terial virulence regulators [69–71] such that its knockdown
may favor certain infections. In a similar manner, human
PON3 also has a protective role against atherosclerosis and
obesity [1, 33–35], but interpretation is complicated by
the fact that there are conﬂicting reports on its expression
pattern, which also varies with the species. Marsillach
et al. found PON3 by immunohistochemistry in human
aortic walls and macrophages [72], while we did not detect
human PON3 message or protein in immortalized EA.hy
926 macrovascular endothelial cells, in primary HUVECs
(human umbilical vein endothelial cells), SMCs (human
coronary artery smooth muscle cells), or AoAFs (aortic
adventitial ﬁbroblasts; [24] and data not shown); this
makes it diﬃcult to reveal the mechanistic site of action.
Moreover, human PON3 is present on HDL particles and
absent in macrophages while the opposite is true for mice
[1, 27]. In general, it has been postulated that human
PON3 exerts its (antiatherogenic) function rather inside
than outside the cells [35, 73], similar to PON2 and likely
diﬀerent from PON1. Studies performed by Shih et al. also
revealed a role for PON3 in lipid metabolism that links
to adiposity; intriguingly, this was gender-speciﬁc for yet
unknown reasons [35]. Collectively, PON2 and PON3 have
protective functions in cardiovascular diseases, and PON2
plays a dominant role in antibacterial defense, such that
an untargeted knockdown may favor these illnesses. As a
consequence, a systemic downregulation of PON2 or PON3
does not seem advantageous, as it likely causes a range of
s e r i o u ss i d ee ﬀects.
Given that PON2/PON3 protect against atherosclerosis
and stabilize atherosclerotic plaques (see above and [33,
36, 74]), may their upregulation then be beneﬁcial to
combat atherosclerosis? This is a relevant aspect given the
overall number of deaths caused by cardiovascular diseases,
which outnumber all cancers [75]. We would ﬁrst need
to determine if enforced PON2/PON3 expression blocks
progression or, under optimal conditions, causes regression
of established atherosclerotic plaques. Overexpression has
been shown to prevent atherogenesis in murine models
[25, 33, 35, 36, 74]; however, in clinical reality, patients show
up with fully established plaques and need alleviating care,
as it is too late for prophylactic approaches. Yet, there is little
[33] or no evidence if PONs block progression of established
plaques or even cause regression, perhaps due to their
anti-inﬂammatory eﬀects. Should such studies be positive,
how can we exploit the beneﬁcial eﬀects of PON2/PON3
against atherosclerosis while concomitantly avoiding their
pro-oncogenic function? The ﬁrst step is the identiﬁcation of
pathways regulating PON expression and the identiﬁcation10 Journal of Lipids
of lead substances increasing or decreasing endogenous
levels.Then,onesolutionmaycomefromdrug-elutingstents
implanted into the atherosclerotic vascular wall—an already
established clinical application. This would allow an upregu-
lation of PON2/PON3 directly in the diseased vessel without
promoting tumor formation in distant organs. Another
solution may come from the speciﬁc targeting of eﬀector
moleculesorpathways(oncetheyareidentiﬁed)forexample,
via surface receptors—a likely realistic mission given the
accessibility of the vascular wall. In turn, similar approaches
could be useful to downregulate PONs in cancer tissues. It
would also be valuable to inhibit the interaction of PONs
with coQ10 as this could block their antioxidative eﬀect and
render these enzymes useless for cancer cells. Finally, the
time line may be advantageous in consideration of slow-
progressing atherosclerosis and fast-progressing tumors; in
some cases this may allow transient downregulation of
paraoxonases to boost eﬃcacy of anticancer therapies while
not immediately causing plaque formation.
In summary, there exists a remarkable twist in the
paraoxonase ﬁeld since we know that PON2 and PON3
protect against cardiovascular diseases but favor tumor
formation. It will be exciting to await further developments
and the usefulness of these enzymes in the ﬁght against two
of the most signiﬁcant human diseases.
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